M&A Deal Summary

Clario Acquires APDM Wearable Technologies

On June 10, 2020, Clario acquired medical products company APDM Wearable Technologies

Acquisition Highlights
  • This is Clario’s 3rd transaction in the Medical Products sector.
  • This is Clario’s 7th transaction in the United States.
  • This is Clario’s 1st transaction in Oregon.

M&A Deal Summary
Date 2020-06-10
Target APDM Wearable Technologies
Sector Medical Products
Buyer(s) Clario
Deal Type Add-on Acquisition

Target

APDM Wearable Technologies

Portland, Oregon, United States
APDM, Inc. is a digital health company that offers sensor-based solutions for quantifying human movement. APDM has raised $13MM+ from the NIH and Department of Defense, has over 200+ publications and thousands of researchers worldwide using our technology, and is currently involved in multiple clinical trials. The company is a full-stack engineering team (hardware, software, algorithm) with a strong scientific foundation. APDM was formed in 2007 and is based in Portland, Oregon.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Clario

Philadelphia, Pennsylvania, United States
Category Company
Founded 1972
Sector Medical Products
Employees3,800
DESCRIPTION

Clario offers a compelling combination of technology, services, and clinical expertise, helping customers to deliver successful clinical trial outcomes by ensuring high-quality data capture, reduced costs, and shortened study timelines. Clario was founded in 1972 and is based in Philadelphia, Pennsylvania.

DEAL STATS #
Overall 8 of 10
Sector (Medical Products) 3 of 3
Type (Add-on Acquisition) 6 of 7
State (Oregon) 1 of 1
Country (United States) 7 of 8
Year (2020) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2017-12-04 iCardiac Technologies

Rochester, New York, United States

iCardiac Technologies, Inc. is a provider of advanced cardiac safety analysis technologies. The company evolved from research carried out at the Heart Research Follow-up Program at the University of Rochester. The company's technology provides more rigorous characterization of the cardiac safety profiles of in-development and on-market drugs.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-12-10 BioClinica

Princeton, New Jersey, United States

Bioclinica is an integrated clinical life science solutions provider, delivering powerful insight into clinical trial development, assuring greater client success in bringing medical therapies to market, for people around the world. Through deep medical, scientific, and technology expertise, the company provides medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments; clinical trial management software; and drug safety solutions. Bioclinica’s global team of life science experts serves more than 500 pharmaceutical, biotechnology, and device organizations including the top 20 biopharmaceutical companies and leading CROs through offices in North America, Europe, and Asia. Bioclinica was formed in 1990 and is based in Princeton, New Jersey.

Buy -
Mergr

Product

Company

Legal